Relay Therapeutics, Inc. (RLAY) Financials

RLAY Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 699.6 million 57.4 million
Dec. 31, 2025 621.3 million 54.3 million
Sept. 30, 2025 670.0 million 62.3 million
June 30, 2025 728.8 million 63.2 million

RLAY Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -51.1 million 10.5 million
Dec. 31, 2025 -44.9 million 13.1 million
Sept. 30, 2025 -62.1 million 15.5 million
June 30, 2025 -55.3 million 14.5 million

RLAY Net Income

No data available :(

RLAY Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 642.1 million - 27.7 million
Dec. 31, 2025 554.5 million - 28.7 million
Sept. 30, 2025 596.4 million - 33.3 million
June 30, 2025 656.8 million - 34.2 million

RLAY Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 179.8 million
Dec. 31, 2025 171.6 million
Sept. 30, 2025 172.4 million
June 30, 2025 171.3 million

RLAY Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 70.6 million 11.0 million -
Dec. 31, 2025 1000 55.4 million 13.0 million -
Sept. 30, 2025 1000 68.3 million 12.1 million -
June 30, 2025 26000 63.9 million 13.6 million -

RLAY Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 3.0 million 504000
Dec. 31, 2025 7.0 million 599000
Sept. 30, 2025 - 748000
June 30, 2025 677000 1.0 million

RLAY Revenue by Segment
Graph available only for paid members. Upgrade to see it.

RLAY

Price: $14.96

52 week price:
2.98
17.47

Earnings Per Share: -1.56 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 1.4 million

Market Capitalization: 2.9 billion

Links: